Positive DENALI Part 2a interim data selects 400mg QD 5:2 as pivotal azenosertib dose in Cyclin E1+ ovarian cancer.
The April 9 announcement reported a clearly differentiated objective response rate at the 400mg once-daily 5-on/2-off schedule versus 300mg, with comparable safety, roughly half the adverse-event discontinuation rate of prior data, and no treatment-related deaths. This de-risks the biomarker-driven program, enabling advancement in the potentially pivotal DENALI Phase 2 (topline expected by year-end 2026) and confirmatory ASPENOVA Phase 3 (initiation in Q2 2026), while supporting pre-commercial activities and pipeline expansion. Fast Track designation adds regulatory momentum. Follow-through buying and an analyst price target increase amplified gains into April 10. (Sources: company press release via GlobeNewswire, SEC filing, analyst notes.)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.